As shown in Table 1, when the entire cohort of the 653 PTC cases was divided into two genotype groups—a BRAF V600E mutation group and a wild-type BRAF group, the BRAF mutation group was significantly associated with older patient age (P = 0.031), larger tumor size (P = 0.006), capsular invasion (P = 0.027), extrathyroidal invasion (P = 0.004), lymph node metastasis (LNM) (P = 0.035), advanced stage (P = 0.005) and higher MAICS score (P < 0.001). The gene discussed is BRAF; the disease is metastatic malignant neoplasm in the lymph nodes.